Zobrazeno 1 - 10
of 101
pro vyhledávání: ''
Publikováno v:
BMC Cancer
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
Background A number of protein markers have been investigated as prognostic adjuncts in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. Recently, we showed that BCL2 protein expression
Autor:
Anupam Batra, C. Michael DiPersio, Anshu Aggarwal, David M. Jones, Rami N. Al-Rohil, Paul J. Feustel
Publikováno v:
BMC Cancer
Background Expression of integrin α3β1 is associated with tumor progression, metastasis, and poor prognosis in several cancers, including breast cancer. Moreover, preclinical studies have revealed important pro-tumorigenic and pro-metastatic functi
Autor:
Taher Al-Tweigeri, Ayodele Alaiya, Abdelilah Aboussekhra, Nujoud Al-Yousef, Suad M. Bin Amer, Nisreen Al-Moghrabi, Safia Madkhali, Asma Tulbah, Asmaa Nofel, Zakia Shinwari, Bedri Karakas
Publikováno v:
BMC Cancer
Background BRCA1 promoter methylation has been detected in DNA from peripheral blood cells of both breast cancer patients and cancer-free females. However, the pathological significance of this epigenetic change in white blood cells (WBC) remains an
Publikováno v:
BMC Cancer
Background A signal transduction pathway (STP) is a network of intercellular information flow initiated when extracellular signaling molecules bind to cell-surface receptors. Many aberrant STPs have been associated with various cancers. To develop op
Autor:
Yoko Nakasu, Koichi Mitsuya, Nakamasa Hayashi, Junichiro Watanabe, Hideyuki Harada, Ichiro Ito
Publikováno v:
BMC Cancer
Background Multiple new targeted agents have been developed for patients with human epidermal growth factor receptor type 2 (HER2) – positive breast cancer. Patients with HER2– positive breast cancer will develop brain metastases with greater inc
Autor:
Jin Seok Ahn, Yoon-La Choi, Hyun Jung Jun, Yeon Hee Park, Myung Hee Chang, Eun Yoon Cho, Min Jae Park, Young-Hyuck Im, Ji Eun Uhm, Do Hyoung Lim, Sang Hoon Ji, Kyoung Ha Kim, Seong Yoon Yi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
Background We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype. Methods A retrospective analysis
Publikováno v:
BMC Cancer
BMC Cancer, Vol 12, Iss 1, p 257 (2012)
BMC Cancer, Vol 12, Iss 1, p 257 (2012)
Background Sulfotransferase 1A1 (SULT1A1) participates in the elimination of 4-hydroxy-tamoxifen (4-OH-TAM), which is one of the major active metabolites of tamoxifen (TAM). Homozygous SULT1A1 variant allele genotype has been associated with lower ca
Autor:
Xue Qin Yu
Publikováno v:
BMC Cancer
BMC Cancer, Vol 9, Iss 1, p 364 (2009)
BMC Cancer, Vol 9, Iss 1, p 364 (2009)
Background Previous studies have documented lower breast cancer survival among women with lower socioeconomic status (SES) in the United States. In this study, I examined the extent to which socioeconomic disparity in breast cancer survival was expla
Autor:
Jan G. Hengstler, Marco Johannes Battista, D. Boehm, Susanne Gebhard, Antje Lebrecht, Marcus Schmidt, Christine Solbach, W. Siggelkow, Heinz Koelbl, Cristina Cadenas, Rosemarie Marchan, Birte Hellwig, Jörg Rahnenführer, Isabel Sicking, M. Gehrmann
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 562 (2012)
BMC Cancer
BMC Cancer
Background Inhibitors targeting the cell cycle-regulated aurora kinase A (AURKA) are currently being developed. Here, we examine the prognostic impact of AURKA in node-negative breast cancer patients without adjuvant systemic therapy (n = 766). Metho
Autor:
Barbara Perić, Radan Dzodic, Rok Petric, Gasper Pilko, Hana Besic, Jan Zmuc, Nikola Besic, Andraz Perhavec
Publikováno v:
BMC Cancer
Background The population of elderly people is increasing and so is the population of breast cancer patients aged ≥80 years. The aim of our retrospective study was to identify independent prognostic factors for the duration of breast cancer-specifi